Peptide Comparison
TabimorelinvsGHRP-6 (Growth Hormone Releasing Peptide-6)
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
A synthetic hexapeptide that signals your pituitary to release growth hormone through a unique pathway, with emerging evidence of heart-protective benefits.
At a Glance
Quick
comparison
Dose Range
Tabimorelin
100–500 mg
GHRP-6 (Growth Hormone Releasing Peptide-6)
100–300 mcg
Frequency
Tabimorelin
Once daily
GHRP-6 (Growth Hormone Releasing Peptide-6)
Multiple times daily
Administration
Tabimorelin
Oral (capsule or solution)
GHRP-6 (Growth Hormone Releasing Peptide-6)
Subcutaneous injection
Cycle Length
Tabimorelin
4-6 weeks
GHRP-6 (Growth Hormone Releasing Peptide-6)
8-12 weeks
Onset Speed
Tabimorelin
Moderate (1-2 weeks)
GHRP-6 (Growth Hormone Releasing Peptide-6)
Moderate (1-2 weeks)
Evidence Level
Tabimorelin
Moderate human trials (Phase 1-2)
GHRP-6 (Growth Hormone Releasing Peptide-6)
Limited human trials
Efficacy
Benefit
ratings
Growth Hormone Stimulation
Convenience & Compliance
Selectivity & Safety Profile
Muscle Recovery and Growth
Cellular Health and Protection
Appetite and Nutrient Intake
Technical Data
Compound
specifications
Tabimorelin
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 g/mol
Half-Life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS Number
193079-69-5
GHRP-6 (Growth Hormone Releasing Peptide-6)
Molecular Formula
C46H56N12O6
Molecular Weight
873.0 g/mol
Half-Life
~2.5 hours
Bioavailability
<1% oral, high subcutaneous
CAS Number
87616-84-0
Protocols
Dosing
tiers
Tabimorelin
GHRP-6 (Growth Hormone Releasing Peptide-6)
Applications
Best
suited for
Tabimorelin
+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
+Orally active—no injections required, making it convenient for daily use
+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
+Well-tolerated in short-term human studies with generally mild adverse effects
GHRP-6 (Growth Hormone Releasing Peptide-6)
Athletes and Serious Trainers
If you're hitting the gym hard and want better recovery and muscle growth, GHRP-6 amplifies your body's natural GH response. This is particularly valuable during intense training phases when you want to maximize adaptation and minimize soreness. The appetite stimulation also helps you consume the calories you need to grow.
Those Exploring Novel Peptide Protocols
GHRP-6 offers a unique mechanism through the ghrelin receptor, making it valuable for users who want to explore diverse GH-stimulation pathways. It works distinctly from GHRH-based approaches and pairs well with other GH secretagogues for synergistic effects.
Longevity and Metabolic Health Enthusiasts
Growth hormone plays roles in metabolic health, body composition, and potentially aging markers. GHRP-6's emerging research on cellular protection and antioxidant activation makes it interesting for those interested in broader health optimization beyond just muscle growth.
Safety Profile
Side
effects
Tabimorelin
Common
- Headache
- Nausea
- Appetite stimulation
- Dizziness
- Dry mouth
Serious
- Drug-drug interactions via CYP3A4 inhibition
GHRP-6 (Growth Hormone Releasing Peptide-6)
Common
- Increased Appetite
- Mild Joint or Muscle Discomfort
- Water Retention or Mild Swelling
Uncommon
- Sleep Disturbances
- Mild Dizziness or Lightheadedness
Serious
- Allergic Reaction
Research Status
Safety
& evidence
Tabimorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Contraindications
- xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- xUntreated thyroid dysfunction
- xUncontrolled diabetes
GHRP-6 (Growth Hormone Releasing Peptide-6)
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
GHRP-6 has a relatively long research history dating back to 1981, with human studies demonstrating its ability to stimulate GH release. The good news is that animal safety studies show excellent tolerability at high doses, and the side effects reported are generally mild and reversible. However, it's not FDA-approved, so use is based on research evidence rather than pharmaceutical oversight. Always purchase from reputable sources and consider medical consultation, especially if you have existing health conditions.
Contraindications
- xKnown allergy or sensitivity to any component of the peptide
- xActive cancer or history of cancer without medical clearance
- xSevere cardiovascular disease or uncontrolled hypertension
- xAcute critical illness or sepsis
Decision Guide
Which is
right for you?
Choose Tabimorelin if...
- Stimulating growth hormone production in healthy individuals
- Exploring GH secretagogue mechanisms in research settings
- Patients preferring oral administration over injections
Choose GHRP-6 (Growth Hormone Releasing Peptide-6) if...
- Building lean muscle mass and improving body composition
- Recovery from intense training programs and athletic performance
- Supporting overall metabolic health and longevity markers
- Exploring novel GH-stimulation pathways for those who respond well to peptide protocols